35,319 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Acquired by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC acquired a new position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 35,319 shares of the company's stock, valued at approximately $958,000. ADAR1 Capital Management LLC owned approximately 0.06% of Structure Therapeutics at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GPCR. ANTIPODES PARTNERS Ltd lifted its stake in shares of Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after acquiring an additional 553 shares in the last quarter. GAMMA Investing LLC boosted its stake in Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after acquiring an additional 1,122 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in Structure Therapeutics during the 4th quarter worth $40,000. Assetmark Inc. increased its position in shares of Structure Therapeutics by 72.3% in the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company's stock worth $62,000 after purchasing an additional 953 shares during the last quarter. Finally, Headlands Technologies LLC bought a new position in shares of Structure Therapeutics during the fourth quarter worth about $113,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GPCR has been the topic of a number of research analyst reports. William Blair started coverage on Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating on the stock. JMP Securities reissued a "market outperform" rating and set a $91.00 target price on shares of Structure Therapeutics in a report on Wednesday, December 18th. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price objective on shares of Structure Therapeutics in a research report on Thursday, December 19th. Finally, Stifel Nicolaus initiated coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They issued a "buy" rating and a $50.00 target price for the company. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $81.29.

Remove Ads

Structure Therapeutics Stock Performance

Shares of GPCR traded up $0.85 during mid-day trading on Friday, reaching $15.90. 510,397 shares of the company's stock traded hands, compared to its average volume of 869,074. The business's 50-day moving average price is $20.98 and its 200-day moving average price is $29.19. The stock has a market capitalization of $911.75 million, a P/E ratio of -21.49 and a beta of -1.35. Structure Therapeutics Inc. has a 12 month low of $13.22 and a 12 month high of $62.74.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. Equities research analysts anticipate that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.